UW researchers at the Carbone Cancer Center have identified the cells that can cause graft versus host disease, the most common complication of bone marrow transplants.
List view / Grid view
Graft versus Host Disease (GvHD)
While the full potential of gene therapies continues to be realised, their successes in rare diseases promote them as a promising treatment modality. Dr Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals discusses the future of gene therapies as well as the company’s progress in in vivo and ex vivo programmes.